A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies

E. D. Ellis, S. F. Williams, J. A. Moormeier, L. S. Kaminer, J. D. Bitran

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Twenty-five patients with refractory solid tumors were treated with high-dose cyclophosphamide, thiotepa and mitoxantrone followed by autologous stem cell rescue in a phase I dose escalation study. The dose-limiting toxic effect was mucositis at 60 mg/m2 of mitoxantrone in combination with cyclophosphamide and thiotepa. The early death rate due to toxic effects was 24%; all deaths were attributed to infections. Hematopoietic recovery was quite prolonged with median times to granulocyte (>500 x 106/l) and platelet (>50 x 109/l) recovery at 58 and 148 days, respectively. The overall response rate was 56%. The median time to progression was 14 weeks. Thus, this regimen has activity against refractory malignancies although early and prohibitive toxicity occurs when mitoxantrone is escalated in this setting.

Original languageEnglish (US)
Pages (from-to)439-442
Number of pages4
JournalBone Marrow Transplantation
Volume6
Issue number6
StatePublished - 1990
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies'. Together they form a unique fingerprint.

Cite this